Do you want to read an article? Please log in or register.
Clinical implications of food-drug interactions with small-molecule kinase inhibitors
Further Publications
Related content
Breast Cancer
Clinical Management of Potential Toxicities and Drug Interactions Related to Cyclin-Dependent Kinase 4/6 Inhibitors in Breast Cancer: Practical Considerations and Recommendations
Oncologist.
Spring LM, Zangardi ML, Moy B, Bardia A
doi: 10.1634/
Lung, Respiratory and Thoracic Cancer
Safety and Tolerability of Anaplastic Lymphoma Kinase Inhibitors in Non-Small-Cell Lung Cancer
Drug Saf.
Rocco D, Battiloro C, Della Gravara L, Gridelli C
doi: 10.1007/s40264-018-0771-y.
Lung, Respiratory and Thoracic Cancer
Clinical utility of plasma-based digital next-generation sequencing in oncogene-driven non-small-cell lung cancer patients with tyrosine kinase inhibitor resistance
Lung Cancer.
Zugazagoitia J, Gómez-Rueda A, Jantus-Lewintre E, Isla D, Camps C, Ramos I, Trigo JM, Bernabé R, Juan-Vidal O, Sanchez-Torres JM, García-Campelo R, Provencio M, Felip E, de Castro J, Faull I, Lanman RB, Ponce-Aix S, Paz-Ares L, Garrido P
doi: 10.1016/j.lungcan.
Lung, Respiratory and Thoracic Cancer
Clinical and Molecular Characteristics Associated With Survival Among Patients Treated With Checkpoint Inhibitors for Advanced Non-Small Cell Lung Carcinoma: A Systematic Review and Meta-analysis
JAMA Oncol.
Lee CK, Man J, Lord S, Cooper W, Links M, Gebski V, Herbst RS, Gralla RJ, Mok T, Yang JC
doi: 10.1001/
Lung, Respiratory and Thoracic Cancer
Resistance to EGFR inhibitors in non-small cell lung cancer: Clinical management and future perspectives
Crit Rev Oncol Hematol.
Tomasello C, Baldessari C, Napolitano M, Orsi G, Grizzi G, Bertolini F, Barbieri F, Cascinu S
doi: 10.1016/j.critrevonc.
Lung Cancer
Molecular Diagnostic and Precision Medicine in Non-Small Cell Lung Cancer. An Update on the Treatment of the Most Important Actionable Oncogenic Driver Alterations.
1Department of Medical Oncology, University Hospital Basel, Basel, Switzerland.
COMMENTED
Leukemia
Assessment of Outcomes After Stopping Tyrosine Kinase Inhibitors Among Patients With Chronic Myeloid Leukemia: A Nonrandomized Clinical Trial
★ 2
Recommended and commented by
Prof. Dr Christoph Renner, Faculty Member
JAMA Oncol.
Atallah E, Schiffer CA, Radich JP, Weinfurt KP, Zhang MJ, Pinilla-Ibarz J, Kota V, Larson RA, Moore JO, Mauro MJ, Deininger MWN, Thompson JE, Oehler VG, Wadleigh M, Shah NP, Ritchie EK, Silver RT, Cortes J, Lin L, Visotcky A, Baim A, Harrell J, Helton B, Horowitz M, Flynn KE
doi: 10.1001/jamaoncol.2020.5774.
Lung, Respiratory and Thoracic Cancer
Biomarkers for the Clinical Use of PD-1/PD-L1 Inhibitors in Non-Small-Cell Lung Cancer: A Review
JAMA Oncol.
Sacher AG, Gandhi L
doi: 10.1001/jamaoncol.2016.0639.
Lung, Respiratory and Thoracic Cancer
Ensartinib vs Crizotinib for Patients With Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer: A Randomized Clinical Trial
JAMA Oncol
Horn L, Wang Z, Wu G, Poddubskaya E, Mok T, Reck M, Wakelee H, Chiappori AA, Lee DH, Breder V, Orlov S, Cicin I, Cheng Y, Liu Y, Fan Y, Whisenant JG, Zhou Y, Oertel V, Harrow K, Liang C, Mao L, Selvaggi G, Wu YL
doi: 10.1001/jamaoncol.2021.3523